Humanigen — Corporate Update (November 2020)
17 slides from Humanigen's corporate update, Nov 6, 2020
Slide 1: Humanigen November 2020
Humanigen November 2020 Humanigen
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Cautionary Note Regarding Forward - Looking Statements All statements other than statements of historical facts contained in this presentation, including information concerning the of fering, our possible or assumed future results of operations and expenses, business strategies and plans, competit
Slide 3: Agenda
3 Agenda • Introduction Cameron Durrant, CEO • Phase 3 update Dale Chappell, CSO • CRADA/OWS Tim Morris COO/CFO • Questions All
Slide 4: Positive Interim Phase 3 Data of Lenzilumab in COVID-19
4 Positive Interim Phase 3 Data of Lenzilumab Ρ in COVID - 19 • Current enrollment is 300 patients • Interim analysis conducted on the first 165 patients • Estimated 37% more recoveries observed with lenzilumab vs current standard of care • Phase 3 study is tracking to a successful outcome with a st
Slide 5: Understanding the Interim DSMB Analysis
5 Lenzilumab Phase 3 - Understanding the Interim DSMB Analysis • Time to event analysis has four components (p - value, power, events, hazard ratio) • G iven three of the four components, the fourth component can be derived from the other three • P - value is fixed at p=0.05 • Power is selected by H
Slide 6: Primer on Hazard Ratio
6 Lenzilumab Phase 3 - Primer on Hazard Ratio • Hazard ratio compares events ( recoveries) observed in the treatment arm of the study compared to the control across all the time points through day 28 (E t / E c ), where E t and E c are events in the treatment arm and control arm • HR=1.0 means that
Slide 7: Lenzilumab Phase 3 Adaptive Trial Design
7 Lenzilumab Phase 3 Adaptive Trial Design • Humanigen’s phase 3 study is an adaptive trial design • Initial trial design included n=300 to generate 257 events • Trial designed as “real world”, patients allowed access to remdesivir and steroids as background SOC in both arms. All patients, whether i
Slide 8: Adaptive Trial Design
8 Lenzilumab Phase 3 - Adaptive Trial Design 50% HR=1.50 HR=1.29 HR ≤ 1.0 % Increase in sample size 25% 50% 10% S teroids and/or remdesivir Baricitinib 1 Tocilizumab 2 HR=1.16 Lenzilumab 3 HR=1.37 1 ACTT - 2 2 EMPACTA 3 Lenzilumab HR based on observed interim analysis with the large majority of pati
Slide 9: Interim Analysis Interpretation
9 Lenzilumab Phase 3 - Interim Analysis Interpretation * Benefit that is in addition to any benefit from steroids and/or remdesivir in the control arm • Patient characteristics for first 165 patients show good distribution of • Disease severity • Age • Diversity • Extensive use of concomitant therap
Slide 10: Interim Analysis Interpretation
10 Lenzilumab Phase 3 - Interim Analysis Interpretation • Based on the first 165 patients (randomized, double - blind, placebo - controlled, multicenter), l enzilumab tracking to a result that is significantly better than steroids and/or remdesivir alone (estimated HR=1.37): • 37% more recoveries on
Slide 11: Interim Analysis Conclusion
11 Lenzilumab Phase 3 - Interim Analysis Conclusion • Lenzilumab treatment tracking better than standard of care • Phase 3 study being expanded, a dditional study sites being added • 90% powering maintained • Program significantly de - risked • EUA filing expected Q1 2021 • Interim efficacy analysis
Slide 12: CRADA and Operation Warp Speed
12 CRADA and Operation Warp Speed CRADA signed with Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO - CBRND) • In collaboration with Biomedical Advanced Research and Development Authority (BARDA) • Part of Assistant Secretary for
Slide 13: Key Members of OWS
13 Key Members of OWS • Moncef Slaoui • General Gustave Perna • Janet Woodcock • Carlo De Notaristefano • Colonel Deacon Maddox • Lt. General Paul Ostrowski
Slide 14: OWS Regulatory Participation and Expertise
14 OWS Regulatory Participation and Expertise • Interim results (unblinded) shared with OWS • OWS therapeutic efforts headed by Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER) at FDA • Review of all submissions and correspondence to FDA • OWS FDA SME attendance at comp
Slide 15: OWS Manufacturing and Supply Chain Expertise
15 OWS Manufacturing and Supply Chain Expertise • Manufacturing experts include Carlo De Notaristefano , Exec VP, Global Ops, Teva • OWS efforts lead by General Gustave Perna , US Army four - star general, Chief Operating Officer (previously served as the 19th commanding general of United States Arm
Slide 16: Benefits of CRADA
16 Benefits of CRADA • Regulatory guidance and assistance provided by FDA experts enhances FDA interaction • Provides to access to BARDA existing relationships with CMOs • Potential for preferential scheduling and capacity allocation • Ability to tap into current stock of critical components • CRADA
Slide 17: Questions and Discussion
17 Questions and Discussion Questions and Discussion